版本:
中国

BRIEF-Kamada Ltd presents updated data from phase 2 clinical trial of inhaled alpha-1-antitrypsin

May 24 Kamada Ltd:

* Kamada Ltd presents updated data from phase 2 clinical trial of inhaled alpha-1-antitrypsin for treatment of alpha-1 antitrypsin deficiency

* Kamada - believe that the findings, as well as previously announced top-line data from this trial, support use of inhaled AAT for treatment of aatd

* Kamada Ltd - expect to have an approved investigational new drug application to conduct a pivotal phase 3 study prior to end of year Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐